Livzon Pharmaceutical Group Inc 2021 SR
The report highlights Livzon Pharmaceutical Group's 2021 ESG performance, focusing on R&D innovation in biopharmaceuticals and the V-01 COVID-19 vaccine. The company achieved a 14.67% increase in operating income and invested RMB 1,523.26 million in R&D. Environmental efforts included a 6.71% reduction in Scope 1 and 2 greenhouse gas emissions and a commitment to carbon neutrality by 2055. Social initiatives featured the 'Public Welfare Project for Prevention and Treatment of Chronic Diseases,' benefiting over 5,000 people in remote areas. The report also details robust quality management systems and a diverse workforce with 47.7% female employees.
Company: Livzon Pharmaceutical Group Inc
Sector: Manufacturing
Country: China
Year: 2021
Type: SR
Pages: 246
Livzon Pharmaceutical Group Inc
The report highlights Livzon Pharmaceutical Group's 2021 ESG performance, focusing on R&D innovation in biopharmaceuticals and the V-01 COVID-19 vaccine. The company achieved a 14.67% increase in operating income and invested RMB 1,523.26 million in R&D. Environmental efforts included a 6.71% reduction in Scope 1 and 2 greenhouse gas emissions and a commitment to carbon neutrality by 2055. Social initiatives featured the 'Public Welfare Project for Prevention and Treatment of Chronic Diseases,' benefiting over 5,000 people in remote areas. The report also details robust quality management systems and a diverse workforce with 47.7% female employees.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees